Atlas Trials

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Clinical trial NCT05262517 · TERMINATED

Trial details

NCT number
NCT05262517
Sponsor
Pfizer
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Temporomandibular Disorders (TMD)
Start date
2022-05-05
Primary completion
2023-05-18
Enrollment
126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.